Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec Reports Third Quarter 2017 Financial Results
Third quarter revenue of $30.4 million, an increase of 17% compared to prior year period Continued growth from both the Tuberculosis (TB) and Tick-borne disease franchises, with double-digit revenue growth in all three geographies served Gross margin improved by 450 basis points on a sequential
View HTML
Toggle Summary Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Announces Update in Patent Infringement Litigation
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec to Present at the Baird 2017 Global Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) --  Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Appoints Stefan Linn as Chief Operating Officer
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Global PLC Announces Pricing of Underwritten Public Offering of Ordinary Shares
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Global PLC Announces Agreement to Sell 2,500,000 Ordinary Shares
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Reports Second Quarter 2017 Financial Results
Second quarter revenue of $26.1 million, an increase of 36% compared to prior year period Continued growth from both the Tuberculosis and Tick-borne disease franchises Successful negotiation of a settlement with Statens Serum Institut which will result in substantial future gross margin improvement
View HTML
Toggle Summary Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions,
View HTML